Showing results (241-250 of 280) with videos related to
Sort By:
Pageof 28
Journal of the National Comprehensive Cancer Network : JNCCN|October 6, 2020
Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in OncologyMichael W Deininger, Neil P Shah, Jessica K Altman, et al.Journal of the National Comprehensive Cancer Network : JNCCN|May 16, 2019
Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2019Patrick A Brown, Matthew Wieduwilt, Aaron Logan, et al.Journal of the National Comprehensive Cancer Network : JNCCN|July 10, 2012
Acute lymphoblastic leukemiaJoseph C Alvarnas, Patrick A Brown, Patricia Aoun, et al.Journal of the National Comprehensive Cancer Network : JNCCN|September 6, 2018
Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in OncologyJerald P Radich, Michael Deininger, Camille N Abboud, et al.Blood|June 8, 2017
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemiaEytan M Stein, Courtney D DiNardo, Daniel A Pollyea, et al.Journal for Immunotherapy of Cancer|August 30, 2023
Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3Bijal D Shah, Ryan D Cassaday, Jae H Park, et al.Science Translational Medicine|March 9, 2018
Exploiting an Asp-Glu "switch" in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemiaFlorence F Wagner, Lina Benajiba, Arthur J Campbell, et al.Blood|April 7, 2021
KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 resultsBijal D Shah, Michael R Bishop, Olalekan O Oluwole, et al.Leukemia|March 20, 2025
Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3Bijal D Shah, Ryan D Cassaday, Jae H Park, et al.Blood Advances|February 24, 2026
No clear benefit of cellular therapy consolidation for patients achieving remission after post-HCT AML relapseH Moses Murdock, Haesook T Kim, Katie Maurer, et al.Pageof 28